Allogene Therapeutics (ALLO) Cash & Equivalents (2018 - 2026)

Allogene Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $30.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 20.52% year-over-year to $30.3 million; the TTM figure through Mar 2026 stood at $30.3 million (down 20.52% YoY), while the FY2025 annual figure was $51.7 million, down 31.28% from the prior year.
• Cash & Equivalents came in at $30.3 million for Q1 2026 at Allogene Therapeutics, down from $51.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $161.5 million in Q2 2024 to a low of $11.8 million in Q4 2022.
• A 5-year average of $71.8 million and a median of $69.2 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 89.85% in 2022 and jumped 607.1% in 2023, its largest moves.
• Allogene Therapeutics' Cash & Equivalents stood at $11.8 million in 2022, then surged by 607.1% to $83.2 million in 2023, then retreated by 9.54% to $75.2 million in 2024, then slumped by 31.28% to $51.7 million in 2025, then tumbled by 41.36% to $30.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $30.3 million, $51.7 million, and $31.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison